首页> 外文OA文献 >Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment

【2h】

Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment

机译：制定全球经济模式，以评估使用伴随癌症治疗伴治疗靶向治疗的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K. Mathurin; C. Beauchemin; J. Lachaine;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 硼中子俘获治疗作为癌症治疗方式的现实评估 [J] . Rolf F.Barth, Zizhu Zhang, Tong Liu 癌症（英文版） . 2018,第007期
2. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models [J] . Lan Gao, Shu-Chuen LI Applied health economics and health policy . 2019,第3期

机译：使用双重救生和马尔可夫模型进行澳大利亚二线高龄或转移性鳞状非小细胞肺癌的核心水平的经济评价
3. Economic evaluation study (CHEER-compliant) Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial [J] . Zhou Jing, Zhao Rongce, Wen Feng, Medicine. . 2016,第27期

机译：经济评估研究（符合CHEER要求）基于CALGB 80405试验的RAS筛查用于治疗转移性结直肠癌的成本效益分析
4. Economic evaluation study (CHEER-compliant) Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial [J] . Zhou Jing, Zhao Rongce, Wen Feng, Medicine. . 2016,第27期

机译：基于CalgB 80405试验的经济评估研究（CheS＆Completient）RAS筛查的成本效果分析
5. A Miniature Bio-Photonics Companion Diagnostics Platform for Reliable Cancer Diagnosis and Treatment Monitoring (BioCDx) [C] . Ernst Lindhout International Molecular Medicine Tri-Conference. . 2019

机译：一种微型生物光子伴诊断平台可靠性癌症诊断和治疗监测（Biocdx）
6. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
7. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea [O] . Eun-A Lim, Haeyoung Lee, Eunmi Bae, 2011

机译：韩国晚期非小细胞肺癌患者EGFR突变和一线靶向治疗的同伴诊断测试的经济评估
8. PRM93 Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer [O] . Mathurin K., Beauchemin C., Lachaine J. 2014

机译：PRM93验证了一种全球经济模型，以评估针对性疗法的成本-效果，该疗法在伴随/诊断转移性结直肠癌中使用克拉斯检验的西妥昔单抗疗法用于晚期/转移性癌症治疗中的伴随诊断

Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment

著录项

引文网络

相似文献

相关主题

期刊订阅